These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19301038)

  • 1. Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols.
    Wesseling-Perry K; Harkins GC; Wang HJ; Sahney S; Gales B; Elashoff RM; Jüppner H; Salusky IB
    Pediatr Nephrol; 2009 Jul; 24(7):1355-61. PubMed ID: 19301038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.
    Salusky IB; Goodman WG; Sahney S; Gales B; Perilloux A; Wang HJ; Elashoff RM; Jüppner H
    J Am Soc Nephrol; 2005 Aug; 16(8):2501-8. PubMed ID: 15944337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Defining the role of sevelamer chloride as a therapeutic agent for management of phosphate in patient with hemodialysis].
    Hashimoto N; Miyata M; Sato N; Mochizuki T; Koike T
    Clin Calcium; 2005 Sep; 15 Suppl 1():30-4; discussion 34. PubMed ID: 16272626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical analysis of time-course changes in minerals and parathyroid hormone levels during treatment with phosphate binders in hemodialysis patients with secondary hyperparathyroidism].
    Yokoyama T; Onodera Y; Mano T
    Clin Calcium; 2005 Sep; 15 Suppl 1():125-30; discussion 130-1. PubMed ID: 16272644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Sevelamer hydrochloride and K/DOQI guidelines].
    Yumita S
    Clin Calcium; 2005 Sep; 15 Suppl 1():180-4. PubMed ID: 16279022
    [No Abstract]   [Full Text] [Related]  

  • 6. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.
    Chudek J; Piecha G; Kokot F; Wiecek A
    J Nephrol; 2003; 16(5):710-5. PubMed ID: 14733418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial.
    Bleskestad IH; Bergrem H; Hartmann A; Godang K; Gøransson LG
    BMC Nephrol; 2012 Jun; 13():49. PubMed ID: 22742720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sevelamer with and without calcium and vitamin D: observations from a long-term open-label clinical trial.
    Chertow GM; Dillon MA; Amin N; Burke SK
    J Ren Nutr; 2000 Jul; 10(3):125-32. PubMed ID: 10921533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment with phosphate binder (sevelamer hydrochloride, calcium carbonate) based on PTH].
    Sato M; Fukazawa S; Yasuda T; Akatsuka T; Tozawa S; Niida Y; Hashimoto N; Mochizuki T; Koike T
    Clin Calcium; 2005 Sep; 15 Suppl 1():23-8; discussion 28-9. PubMed ID: 16272625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study.
    Sadek T; Mazouz H; Bahloul H; Oprisiu R; El Esper N; El Esper I; Boitte F; Brazier M; Moriniere P; Fournier A
    Nephrol Dial Transplant; 2003 Mar; 18(3):582-8. PubMed ID: 12584283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of secondary hyperparathyroidism resistant to conventional therapy and tertiary hyperparathyroidism with Cinacalcet: an efficiency strategy].
    Jean G; Vanel T; Terrat JC; Hurot JM; Lorriaux C; Mayor B; Deleaval P; Vovan C; Chazot C
    Nephrol Ther; 2010 Apr; 6(2):105-10. PubMed ID: 20185380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis.
    Arenas MD; Alvarez-Ude F; Torregrosa V; Gil MT; Carretón MA; Moledous A; Nuñez C; Devesa R; Albiach B
    J Nephrol; 2007; 20(4):453-61. PubMed ID: 17879212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of MBD parameters in dialysis patients by a switch to, and combined use of lanthanum carbonate: Josai Dialysis Forum collaborative study.
    Shinoda T; Yamasaki M; Chida Y; Takagi M; Tanaka Y; Ando R; Suzuki T; Tagawa H
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():29-34. PubMed ID: 23586510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients.
    Liu YL; Lin HH; Yu CC; Kuo HL; Yang YF; Chou CY; Lin PW; Liu JH; Liao PY; Huang CC
    Ren Fail; 2006; 28(8):701-7. PubMed ID: 17162430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of sevelamer to examine the role of intraluminal phosphate in the pathogenesis of secondary hyperparathyroidism.
    Phelps KR; Stote KS; Mason D
    Clin Nephrol; 2014 Sep; 82(3):191-201. PubMed ID: 25079864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
    Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relationship between serum calcium level and PTH concentration proved with sevelamer hydrochloride].
    Ito M; Mochizuki T; Koike T; Hashimoto N; Fukazawa S; Akatsuka T; Niida Y; Tozawa S; Yasuda T; Sato M
    Clin Calcium; 2005 Sep; 15 Suppl 1():11-13; discussion 13-4. PubMed ID: 16279016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients.
    Ferreira A; Frazão JM; Monier-Faugere MC; Gil C; Galvao J; Oliveira C; Baldaia J; Rodrigues I; Santos C; Ribeiro S; Hoenger RM; Duggal A; Malluche HH;
    J Am Soc Nephrol; 2008 Feb; 19(2):405-12. PubMed ID: 18199805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.